Scientists, led by Richard DiMarchi and Matthias Tschöp, are questioning whether targeting the GLP-1 hormone is essential for effective weight loss, a premise that has driven the development of current obesity drugs like Eli Lilly’s Zepbound. They have developed an experimental drug that focuses on receptors for the GIP and glucagon hormones, suggesting that it may achieve weight loss comparable to GLP-1-based treatments without common side effects like nausea. While promising results in animal studies were reported, further testing in humans is necessary, and their findings could challenge existing beliefs in obesity treatment approaches.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.statnews.com/2026/04/16/glp1-weight-loss-new-approach/
